modified EVs with anti‐cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) (anti‐CD19 CAR–EVs) to target CD19‐positive Burkitt lymphoma cells. Here, CD19 is linked to Burkitt lymphoma.